GlassScriptPhysician profile
Jeffrey Quincy Munro
NPI 1205027836
$15,112.34
in general payments reported to CMS, 2019-2025
33 companies · $1,217 in 2025
The $1,217 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,502 · 2020: $1,445 · 2021: $2,496 · 2022: $1,948 · 2023: $3,019 · 2024: $1,485 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,250 · Travel and Lodging: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,249.79 |
| Travel and Lodging | $471.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,568.03 | 2019-2025 | Sq-Rx Pulse Generator, General - Tachy, General - Therapies |
| Abbott Laboratories | $5,105.84 | 2019-2025 | Gallant, Assurity, Ensite |
| Medtronic Vascular, INC. | $662.93 | 2019-2020 | |
| Medtronic, INC. | $635.94 | 2021-2023 | Micra, Cobalt Dr Mri Surescan |
| Biotronik INC. | $621.50 | 2023 | |
| Biosense Webster, INC. | $449.23 | 2021-2024 | Carto 3 |
| Abiomed | $332.94 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $193.52 | 2019-2025 | Lifevest |
| Elutia, INC. | $181.53 | 2021 | |
| Janssen Pharmaceuticals, INC | $162.10 | 2019-2024 | Xarelto |
| Heartflow, INC. | $158.45 | 2023 | Ffrct |
| Novo Nordisk INC | $154.90 | 2023-2025 | Ozempic, Wegovy |
| W. L. Gore & Associates, INC. | $125.87 | 2025 | Gore Excluder Thoracoabdominal Branch Endoprosthesis |
| Bardy Diagnostics, INC. | $125.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $99.35 | 2019-2025 | Camzyos |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $88.80 | 2019-2023 | |
| Cardiva Medical, INC. | $81.75 | 2021 | |
| Edwards Lifesciences Corporation | $52.47 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $52.31 | 2023 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $31.89 | 2023 | |
| Philips North America LLC | $30.31 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $23.43 | 2019 | |
| Lantheus Medical Imaging, INC. | $19.81 | 2024 | |
| Amgen INC. | $19.72 | 2022 | |
| Pfizer INC. | $19.41 | 2025 | |
| Cardinal Health 200 LLC | $17.20 | 2019 | |
| Medicomp INC | $16.60 | 2023 | Telepatch Cardiac Monitor |
| Lundbeck LLC | $15.35 | 2019 | |
| Tactile Systems Technology INC | $14.95 | 2023 | Entre Plus, Flexitouch Plus |
| Alnylam Pharmaceuticals INC. | $14.91 | 2022 | |
| Ethicon US, LLC | $13.96 | 2019 | |
| Atricure, INC. | $11.90 | 2021 | |
| Altathera Pharmaceuticals LLC | $10.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Munro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.